CJC-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== Abiotic stress resistance === Overexpression of systemin and HypSys has been found to improve plants' tolerance to abiotic stress, including salt stress and UV radiation. When prosystemin was over-expressed in tomato, transgenic plants had lower stomatal conductance than normal plants. When grown in salt solutions, transgenic plants had higher stomatal conductances, lower leaf concentrations of abscisic acid and proline and a higher biomass. These findings suggest that systemin either allowed the plants to adapt to salt stress more efficiently or that they perceived a less stressful environment. Similarly, wounded tomato plants were less susceptible to salt stress than unwounded plants. This may be because wounding decreases the growth of the plant and therefore slows the uptake of toxic ions into the roots. An analysis of salt-induced changes in gene expression found that the differences measured between the transgenic and normal plants could not be accounted for by changes in conventional salt stress-induced pathways. Instead Orsini et al. suggested that the activation of the jasmonic acid pathway determines a physiological state that not only directs resources towards the production of compounds active against pests, but also pre-adapts plants to minimize water loss. These effects are achieved by negatively regulating the production of hormones and metabolites that will force plants to invest additional resources to counteract water loss, a secondary effect of herbivores.
On 12 June 1944 U.S. carriers made air strikes on the Marianas, convincing Admiral Soemu Toyoda that the U.S. was preparing to invade. This move came as a surprise; the Japanese had expected the next U.S. target to be further south, either at the Carolines or the Palaus, and had protected the Marianas with only 50 land-based aircraft. On 13–15 June, American carriers made additional airstrikes while surface forces bombarded the Marianas. On 15 June, the first American troops went ashore on Saipan. Since control of the Marianas would bring American strategic bombers within range of the Japanese home islands, the IJN decided it was time for the long-awaited Kantai Kessen (decisive battle). Toyoda immediately ordered a fleet-based counterattack, committing nearly all of the Japanese navy's serviceable ships. The main portions of the fleet rendezvoused on 16 June in the western part of the Philippine Sea and completed refueling on 17 June. Admiral Jisaburō Ozawa commanded this force from his newly commissioned flagship, Taihō. In addition to extensive command facilities, reinforced torpedo blisters and a large air group, Taihō was the first Japanese carrier with an armor-plated flight deck, designed to withstand bomb hits with minimal damage. At 18:35 on 15 June the submarine USS Flying Fish sighted a Japanese carrier and battleship force coming out of the San Bernardino Strait. An hour later USS Seahorse spotted a battleship and cruiser force steaming up from the south, 200 miles (320 km) east of Mindanao.
=== Over-reporting by China === China overwhelmingly dominates the world in reported aquaculture output, reporting a total output which is double that of the rest of the world put together. However, there are some historical issues with the accuracy of China's returns. In 2001, scientists Reg Watson and Daniel Pauly expressed concerns that China was over reporting its catch from wild fisheries in the 1990s. They said that made it appear that the global catch since 1988 was increasing annually by 300,000 tonnes, whereas it was really shrinking annually by 350,000 tonnes. Watson and Pauly suggested this may have been related to Chinese policies where state entities that monitored the economy were also tasked with increasing output. Also, until more recently, the promotion of Chinese officials was based on production increases from their own areas. China disputed this claim. The official Xinhua News Agency quoted Yang Jian, director general of the Agriculture Ministry's Bureau of Fisheries, as saying that China's figures were "basically correct". However, the FAO accepted there were issues with the reliability of China's statistical returns, and for a period treated data from China, including the aquaculture data, apart from the rest of the world.
== External links == HLA-B27 Syndromes at eMedicine by A. Luisa Di Lorenzo, MBBCh Bowness, P. (1 August 2002). "HLA B27 in health and disease: a double-edged sword?". Rheumatology. 41 (8): 857–868. doi:10.1093/rheumatology/41.8.857. PMID 12154202. Online Mendelian Inheritance in Man (OMIM): 142830 HLA-B27 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) BASDAI and Ankylosing Spondylitis National Library of Medicine - Papers on HLA B-27
Sources: en.wikipedia.org
=== Red blood cell transfusions === Blood transfusions are the main treatment approach for prolonging life. Donated healthy red blood cells have a functional life of 4 to 6 weeks before they wear out and are broken down in the spleen. Regular transfusions every three to four weeks are necessary in order to maintain hemoglobin at a healthy level. Transfusions come with risks including iron overload, the risk of acquiring infections, and the risk of immune reaction to the donated cells (alloimmunization).
=== DNA test === The muscle-specific isoform of the dystrophin gene is composed of 79 exons, and DNA testing (blood test) and analysis can usually identify the specific type of mutation of the exon or exons that are affected. DNA testing confirms the diagnosis in most cases.
1993/851) Value Added Tax (General) (Amendment) (No.3) Regulations 1993 (S.I. 1993/856) Social Security (Industrial Injuries and Adjudication) Regulations 1993 (S.I. 1993/861) Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 1993 (S.I. 1993/862) Official Secrets (Prohibited Places) (Amendment) Order 1993 S.I. 1993/863) Devon and Cornwall Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/864) West Mercia Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/865) Sussex Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/866) Avon and Somerset Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/867) Thames Valley Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/868) South Wales Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/869) Education (Designated Institutions in Further and Higher Education) (Interpretation) (Amendment) Order 1993 (S.I. 1993/870) A13 Trunk Road (Newham, Barking and Dagenham, and Havering) (Speed Limits) Order 1988 (Variation) Order 1993 (S.I. 1993/871) Western Isles Islands Council (Lochmaddy) Water Order 1993 (S.I. 1993/872) Oil Related and Petrochemical Plants (Rateable Values) (Scotland) Order 1993 (S.I. 1993/873) Electricity Generators (Rateable Values) (Scotland) Order 1993 (S.I. 1993/874) Scottish Hydro-Electric plc. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/875) Industrial and Freight Transport (Rateable Values) (Scotland) Order 1993 (S.I. 1993/876) Scottish Nuclear Limited (Rateable Values) (Scotland) Order 1993 (S.I. 1993/877) Scottish Power plc.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.